Lex/Who's lobbying/Pharmaceuticals & Life Sciences
EU lobbying · Pharmaceuticals & Life Sciences

Who lobbies the EU on Pharmaceuticals & Life Sciences?

Pharmaceutical and life-sciences companies face EU rules on medicines authorisation, clinical trials and supply-chain integrity across the single market. These are the EU acts most likely to apply.

Organisations19
Disclosed meetings29
SourceEC meeting disclosures
Matched onmedicinal products, clinical trials, veterinary medicinal
In short

19 organisations appear across 29 disclosed European Commission meetings on pharmaceuticals & life sciences; the top listed organisations are AnimalhealthEurope, Access VetMed, European Federation of Pharmaceutical Industries and Associations. EC meeting disclosures Transparency Register

Where do you sit on pharmaceuticals & life sciences?
Run a free exposure scan — see the EU files heading your way and who else is in the room.

Who’s lobbying it

Ranked by distinct disclosed European Commission meetings whose topic matches pharmaceuticals & life sciences keywords. Every organisation links to the official disclosure.

Disclosed meetings

One recent disclosed Commission meeting per organisation, matched to pharmaceuticals & life sciences by topic — each linked to its source.

DateOrganisationDisclosed topic
2026-04-24AnimalhealthEuropeCommission Expert Group on Veterinary Medicinal Products - Article 106(1) of Regulation (EU) 2019/6 source ↗
2026-04-24Access VetMedCommission Expert Group on Veterinary Medicinal Products - Article 106(1) of Regulation (EU) 2019/6 source ↗
2025-02-18European Federation of Pharmaceutical Industries and AssociationsCompetitiveness of the innovative pharmaceutical sector, with specific focus on clinical trials and biotech act. source ↗
2026-02-17European Organisation for Research and Treatment of CancerClinical trials source ↗
2026-04-24Federation of Veterinarians of EuropeCommission Expert Group on Veterinary Medicinal Products - Article 106(1) of Regulation (EU) 2019/6 source ↗
2025-12-05Bristol-Myers Squibb CompanyThe aim of the meeting was to discuss the possible improvements to the Clinical Trials Regulation, IP frameworks and cell therapy in the Biotech Act source ↗
2026-04-24Association of Veterinary ConsultantsCommission Expert Group on Veterinary Medicinal Products - Article 106(1) of Regulation (EU) 2019/6 source ↗
2026-04-15Asociación Agraria Jóvenes AgricultoresLumpy Skin disease (LSD) and vaccination - Veterinary medicinal products source ↗
2025-06-18CITTADINANZATTIVA APSEconomic sustainability of Advanced Therapy Medicinal Products (ATMPs) at the European level. (Meeting convened at request of interest representative following a request made to Director-General, followed up at technical level. source ↗
2025-05-27ALPHAVET Állatgyógyászati Zártkörűen Működő RészvénytársaságAnimal health and veterinary medicinal products source ↗
2025-11-18Miltenyi BiotecBiotechnology and clinical trials source ↗
2025-09-04Magyarországi Klinikai Vizsgálatszervezők TársaságaPromoting multi country clinical trials source ↗
2025-09-04AstraZeneca PLCExchange of views on multinational clinical trials in the context of the upcoming Biotech Act source ↗
2025-09-04SANOFIExchange of views on multinational clinical trials in the context of the upcoming Biotech Act source ↗
2025-06-03Breakthrough T1DPresentation of Breakthrough T1D, the US based, tax-exempt nonprofit organisation that invests in type 1 diabetes research, and discussion on its role as a research funder supporting multicountry clinical trials within the EU source ↗
2025-05-23European Research Infrastructure for Translational MedicinePresentation of EATRIS and a discussion on their role as a clinical research infrastructure supporting multi-country clinical trials within the EU source ↗
2025-05-15European University Hospital AlliancePresentation of the EUHA and a discussion on their role as a network of clinical research hospitals supporting multi-country clinical trials within the EU. source ↗
2025-04-23Biobanking and Biomolecular resources Research Infrastructure-European Research Infrastructure ConsortiumPresentation of BBMRI-ERIC and discussion on their role as clinical research infrastructure to support multi-country clinical trials in EU source ↗
2025-02-04Eli Lilly and CompanyExchange of views on the Clinical Trials Regulation (CTR), In-Vitro Diagnostic Regulation (IVDR) and their interface. Discussion on the clinical trial environment in Europe and globally. source ↗

Related on the graph

The same sector, mapped across the rulebook and the rest of the lobbying record.

Get the EU lobbying brief

We’ll email you when major new lobbying meetings are disclosed — free, no account, built from public EU data with every entry cited. We only email on real updates.

Rankings count distinct disclosed European Commission meetings whose topic matches the sector keywords; they are not a measure of influence or of a position taken. Methodology. Data © European Union (Decision 2011/833/EU).

See your company’s exposure on pharmaceuticals & life sciencesand the rest of the corpus.

Enter your company and Lex builds a cited Exposure Map in about 30 seconds. Free, no login.